NCT01121588 2025-01-23
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Pfizer
Phase 1 Terminated
Clinical Trials
17 trialsNCT01606878 2024-01-05
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT01744652 2023-06-07
Dasatinib and Crizotinib in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02270034 2022-03-10
Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
Grupo Español de Investigación en Neurooncología
Phase 1 Completed
NCT02207504 2022-01-06
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01548144 2021-09-13
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02510001 2021-07-13
MErCuRIC1
University of Oxford
Phase 1 Completed
NCT01531361 2021-01-22
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01579994 2020-12-30
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01999972 2020-09-24
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02511184 2019-07-01
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
Pfizer
Phase 1 Terminated
NCT01644773 2019-03-22
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01576406 2018-10-25
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
Pfizer
Phase 1 Completed
NCT01998126 2018-04-02
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
University of Utah
Phase 1 Completed
NCT02074878 2017-08-09
CRIZENT
Baylor Breast Care Center
Phase 1 Terminated
NCT00965731 2015-10-28
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Pfizer
Phase 1 Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn